Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout : Analysis of a Series of Outpatients
Joint Authors
Carvalho, Mauricio
Buiar, Pedro Grachinski
Giovanella, Laura Helena
Severo, Carolina Rossetti
Azevedo, Valderilio Feijó
Source
International Journal of Rheumatology
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-12
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Objective.
To profile a sample of gouty patients treated with allopurinol, benzbromarone, or a combination of these two drugs and to describe the impact of this therapy in reducing uric acid levels.
Methods.
An observational, transversal study was performed.
We evaluated 48 patients diagnosed with gout who were seen at the Outpatient Rheumatology Clinic of the Federal University of Paraná between January 2009 and November 2010.
Clinical data, creatinine serum levels, and basal and posttreatment levels of serum urates, transaminases, and bilirubins were recorded.
Uric acid levels were measured in a 24-hour urine sample.
Patients were divided into three groups: patients given only allopurinol (A), only benzbromarone (B), and both in combined therapy (A + B).
Results.
The average age of these patients was 56.6 ± 11.4 years, varying from 35 to 81 years.
The entire patient group experienced a significant drop in serum urate levels, from 8.5 ± 1.8 mg/dL (0.472 ± 0.1 mmol/L) to 6.7 ± 2.1 mg/dL (0.372 ± 0.116 mmol/L) (P<0.001), regardless of the prescribed medication.
The number of patients taking both drugs whose serum uric acid values fell within normal range (men <7 mg/dL (0.38 mmol/L) and women <6 mg/dL (0.33 mmol/L)) was 85.7% (6/7) while this value for the group taking benzbromarone alone was 75% (3/4) and for the group taking allopurinol alone this number was 51.8% (14/27).
Conclusions.
The therapeutic combination of benzbromarone and allopurinol significantly decreased serum urate levels in patients with gout when compared to individual use of each of these agents.
This finding is especially important in treating patients who cannot control hyperuricemia with monotherapy.
Benzbromarone alone or in combination with allopurinol has an important clinical role in controlling hyperuricemia in patients with gout.
American Psychological Association (APA)
Azevedo, Valderilio Feijó& Buiar, Pedro Grachinski& Giovanella, Laura Helena& Severo, Carolina Rossetti& Carvalho, Mauricio. 2014. Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout : Analysis of a Series of Outpatients. International Journal of Rheumatology،Vol. 2014, no. 2014, pp.1-5.
https://search.emarefa.net/detail/BIM-458559
Modern Language Association (MLA)
Azevedo, Valderilio Feijó…[et al.]. Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout : Analysis of a Series of Outpatients. International Journal of Rheumatology No. 2014 (2014), pp.1-5.
https://search.emarefa.net/detail/BIM-458559
American Medical Association (AMA)
Azevedo, Valderilio Feijó& Buiar, Pedro Grachinski& Giovanella, Laura Helena& Severo, Carolina Rossetti& Carvalho, Mauricio. Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout : Analysis of a Series of Outpatients. International Journal of Rheumatology. 2014. Vol. 2014, no. 2014, pp.1-5.
https://search.emarefa.net/detail/BIM-458559
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-458559